COSYCHEM

Based in Tianjin, China, and established in 2010, Scaxchem doing business named COSYCHEM, is a pharmaceutical company that engages in R&D, process optimization, and production services of drug intermediates, raw materials of in vitro diagnostic reagents (IVD), and nucleic acid drug raw materials and intermediates. COSYCHEM adopts the business model of Contract Development Manufacturing Organization (CDMO) and Contract Research Organization (CRO). In May 2024, the firm raised a pre-series B funding for CNY 100 million. COSYCHEM'S products can be divided into four categories, pharmaceutical intermediates, PCR materials, nucleic acid drug raw materials, and fluorescence probes.

The pharmaceutical intermediates include azetidine, 3-fluoro azetidine hydrochloride,3-Bromo oxetane, and 3-oxetane carboxylic acid. It also provides molecular block, custom synthesis, and process development services. The company’s revenue is generated by providing small molecule drugs and IVD ingredient CDMO platforms. The company will use the pre-series B funding for the development and commercialization of nucleic acid drugs, delivery systems, in vitro diagnostics and other biotech chemical raw materials and downstream applications.